Article Text

Download PDFPDF
Letter
Several aspects in study design need further consideration
  1. Cheng-Bei Zhou,
  2. Jing-Yuan Fang
  1. Division of Gastroenterology and Hepatology, Shanghai Jiao-Tong University School of Medicine Renji Hospital, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, State Key Laboratory of Oncogene and Related Gene, Shanghai Institute of Digestive Disease, Shanghai, China
  1. Correspondence to Dr Jing-Yuan Fang, Division of Gastroenterology and Hepatology, Shanghai Jiao-Tong University School of Medicine Renji Hospital, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, State Key Laboratory of Oncogene and Related Gene, Shanghai Institute of Digestive Disease, Shanghai, 200001, China; jingyuanfang{at}sjtu.edu.cn

Statistics from Altmetric.com

We read with interest the work by Cheung et al 1 describing that patients with prior Helicobacter pylori eradication therapy receiving long-term proton pump inhibitors (PPIs) therapy are still at enhanced risk of gastric cancer development, particularly for non-cardia cancer. As the current consensus report stated, long-term treatment with PPIs in H. pylori-positive patients accelerates the process of loss of specialised glands, leading to atrophic gastritis. Hence, it is recommended that eradication of H. pylori heals gastritis in patients …

View Full Text

Footnotes

  • Contributors Written by C-BZ. Revised by J-YF.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Correction notice This article has been corrected since it published Online First. The order of the authors has been corrected.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.